scholarly journals Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Denis Ouzan ◽  
Anne Mosnier ◽  
Guillaume Penaranda ◽  
Isabelle Daviaud ◽  
Helene Joly ◽  
...  
Keyword(s):  
Primary Care ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Primary Care Patients ◽  
Significant Liver Fibrosis

Early kidney dysfunction in non-alcoholic fatty liver disease - is transient elastography useful as a screening method?

2021 ◽  
Author(s):  
Marta Freitas ◽  
Vítor Macedo Silva ◽  
Sofia Xavier ◽  
Joana Magalhes ◽  
Carla Marinho ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Transient Elastography ◽  
Screening Method ◽  
Kidney Dysfunction ◽  
Alcoholic Fatty Liver ◽  
Increased Risk ◽  
Significant Liver Fibrosis

Introduction: Increasing evidence suggests an association between metabolic associated fatty liver disease (MAFLD) and chronic kidney disease (CKD). Timely prediction of early kidney dysfunction (EKD) is thus essential in this population, although a screening method is not stablished. We aimed to evaluate the role of transient elastography (TE) in predicting EKD in patients with MAFLD. Methods: Prospective cohort study that included patients with MAFLD scheduled for evaluation, between May/2019 and January/2020. Demographic, clinical and laboratory data, and TE parameters were obtained. EKD was defined as microalbuminuria (urinary albumin-to-creatinine ratio 30-300mg/g) and estimated glomerular filtration rate≥60mL/min/1.73m2. Significant liver fibrosis was defined as liver stiffness measurement (LSM)≥8.2kPa. Results: Included 45 patients with MALFD, 53.3% female gender, mean age of 53.5±10.9years. EKD was found in 17.8% of patients. MAFLD patients with EKD were significantly more obese (body mass index≥30) (75.0% vs 32.4%,p=0.045) and had significantly higher LSM (8.5±4.1 vs 5.8±2.2kPa,p=0.01). After adjustment of potential confounders for EKD the presence of liver fibrosis, remained a significant predictor of EKD, being associated with a 14.3-fold increased risk of EKD (p=0.04). The optimal cutoff value of LSM to predict EKD was 6.1kPa (sensitivity:85.7%; specificity:67.6%). Conclusion: Significant liver fibrosis is associated with a significant increased risk of EKD in patients with MAFLD, regardless of other comorbidities. Higher levels of LSM, particularly >6.1kPa, alert for timely identification of EKD and associated comorbidities, as well as their control, in order to prevent the development of CKD in the long term.

Fibroscan-Based Score to Predict Significant Liver Fibrosis in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease

2020 ◽  
Vol 30 (4) ◽  
pp. 1249-1257 ◽  
Author(s):  
Wei-Yu Kao ◽  
I-Wei Chang ◽  
Chi-Long Chen ◽  
Chien-Wei Su ◽  
Sheng Uei Fang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Morbidly Obese ◽  
Obese Patients ◽  
Nonalcoholic Fatty Liver ◽  
Significant Liver Fibrosis

scholarly journals Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011)

Hepatology ◽  
2016 ◽  
Vol 63 (3) ◽  
pp. 776-786 ◽  
Author(s):  
Yong-ho Lee ◽  
Seung Up Kim ◽  
Kijun Song ◽  
Jun Yong Park ◽  
Do Young Kim ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Significant Liver Fibrosis

SAT-311-The PDGFR-beta containing PRTA-score is a novel non-invasive diagnostic algorithm for significant liver fibrosis in patients with viral, alcoholic, and metabolic liver disease

2019 ◽  
Vol 70 (1) ◽  
pp. e776
Author(s):  
Joeri Lambrecht ◽  
Stefaan Verhulst ◽  
Inge Mannaerts ◽  
jan-peter sowa ◽  
jan best ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Diagnostic Algorithm ◽  
Non Invasive ◽  
Metabolic Liver Disease ◽  
Pdgfr Beta ◽  
Significant Liver Fibrosis

scholarly journals Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis

2016 ◽  
Vol 3 (2) ◽  
Author(s):  
Cecilia T. Costiniuk ◽  
Laurence Brunet ◽  
Kathleen C. Rollet-Kurhajec ◽  
Curtis L. Cooper ◽  
Sharon L. Walmsley ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Liver Disease ◽  
Longitudinal Study ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Tobacco Smoking ◽  
Cohort Analysis ◽  
Tobacco Exposure ◽  
Immunodeficiency Virus ◽  
Significant Liver Fibrosis

Abstract Background.  Tobacco smoking has been shown to be an independent risk factor for liver fibrosis in hepatitis C virus (HCV) infection in some cross-sectional studies. No longitudinal study has confirmed this relationship, and the effect of tobacco exposure on liver fibrosis in human immunodeficiency virus (HIV)-HCV coinfected individuals is unknown. Methods.  The study population consisted of participants from the Canadian Co-infection Cohort study (CTN 222), a multicenter longitudinal study of HIV-HCV coinfected individuals from 2003 to 2014. Data were analyzed for all participants who did not have significant fibrosis or end-stage liver disease (ESLD) at baseline. The association between time-updated tobacco exposure (ever vs nonsmokers and pack-years) and progression to significant liver fibrosis (defined as an aspartate-to-platelet ratio index [APRI] ≥1.5) or ESLD was assessed by pooled logistic regression. Results.  Of 1072 participants included in the study, 978 (91%) had ever smoked, 817 (76%) were current smokers, and 161 (15%) were previous smokers. Tobacco exposure was not associated with accelerated progression to significant liver fibrosis nor with ESLD when comparing ever vs never smokers (odds ratio [OR] = 1.06, 95% confidence interval [CI], 0.43–1.69 and OR = 1.20, 95% CI, 0.21–2.18, respectively) or increases in pack-years smoked (OR = 1.05, 95% CI, 0.97–1.14 and OR = 0.94, 95% CI, 0.83–1.05, respectively). Both time-updated alcohol use in the previous 6 months and presence of detectable HCV ribonucleic acid were associated with APRI score ≥1.5. Conclusions.  Tobacco exposure does not appear to be associated with accelerated progression of liver disease in this prospective study of HIV-HCV coinfected individuals.

scholarly journals Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease

2021 ◽  
Vol 20 ◽  
pp. 100253
Author(s):  
José Tadeu Stefano ◽  
Laura Vilar Guedes ◽  
Arthur Alencar Arrais de Souza ◽  
Denise Siqueira Vanni ◽  
Venâncio Avancini Ferreira Alves ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Collagen Type ◽  
Collagen Type Iv ◽  
Nonalcoholic Fatty Liver ◽  
Type Iv ◽  
Significant Liver Fibrosis

THU-429-Serial testing with the enhanced liver fibrosis test and liver stiffness is cost-effective for detection of advanced alcoholic liver disease in primary care

2019 ◽  
Vol 70 (1) ◽  
pp. e345-e346
Author(s):  
Maja Thiele ◽  
Lars Asphaug ◽  
Aleksander Krag ◽  
Hans Olav Melberg
Keyword(s):  
Primary Care ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Alcoholic Liver Disease ◽  
Liver Stiffness ◽  
Cost Effective ◽  
Serial Testing
Sign in / Sign up

Export Citation Format

Share Document